Bli medlem
Bli medlem

Du är här

2019-02-28

ExpreS2ion Biotechnologies: ExpreS2ion conducts a directed share issue to accelerate the development of the company

ExpreS2ion Biotech Holding AB ("ExpreS2ion") today announces that the
Company is conducting a directed share issue to a number of existing
shareholders and strategic investors of initially approx. SEK 8
million, with attached consideration-free warrants, which in later
stages can provide the Company with a further approx. SEK 9.6
million. The directed share issue is conducted in order to finance an
accelerated pace of operations and increased investments in the
business to ensure long-term good development. The motive to deviate
from the shareholders' preferential rights is that considers it
beneficial for the Company and the shareholders to strengthen the
owner base partly by broadening the base of major shareholders, and
partly by enabling share ownership for new strategic investors with
special interest in the Company, and to avail of the opportunity to
add new working capital to conditions attractive to the Company
(especially the time and cost aspect of the implementation of the
capitalisation). Through the directed share issue, the Company is
supplied with working capital in order to work towards set goals, in
a cost and time-efficient manner and thereby strengthen the Company's
financial position. The above aspects as well as the prevailing
market conditions have resulted in the conclusion that, according to
the Board's opinion, there have been predominant reasons for
deviating from the shareholders' preferential rights to the benefit
of the Company and the shareholders in the long term. The directed
share issue is subject to approval by an Extraordinary General
Meeting, which is planned to be held on March 19, 2019. Notice to
Extraordinary General Meeting is scheduled to be published shortly.

CEO Dr. Steen Klysner comments

"After completing the investments in the platform, our main focus is
now on marketing, where we expect our work to lead to a significant
increase in revenue for the core business in 2019. Furthermore, our
updated platform, with the synergies of AdaptVac's VLP technology,
positions us more strongly in favour of setting up new partnerships,
improving our development capacity for new drug and vaccine assets
and also to create new joint ventures with additional value added. In
order for us to realise our potential and create additional value for
our shareholders, we are now conducting this directed share issue in
order to consolidate our CRO business, take a greater control over
the projects we are active in, and also enable us to establish new
joint ventures."

Motive for the directed share issue

ExpreS2ion has a need for an accelerated pace of operations and
increased investments in the business to ensure long-term good
development. Areas that, in particular, according to the Board, need
expanded investments include continuous development of the Company's
technology platform to ensure that it remains attractive and relevant
to the pharmaceutical and vaccine development industry. In addition,
continued investments are needed in the Company's commercialisation
activities to ensure that the Company's scope for new potential
customers and partners is not limited. Based on the above analysis,
the Board has established three main focus areas for ExpreS2ion's way
forward: further development of the CRO part of ExpreS2ion's core
business, increased investments in the Company's pipeline and a
possible establishment of one or more new joint ventures. These also
constitute the basis for the use of the capital that is acquired
through the current directed issue. The Board's long-term goal for
the Company's development is to develop ExpreS2ion from providing
services in the biotechnology sector, to becoming a growing and
independent pharmaceutical company with proprietary and leading
technologies for drug and vaccine development.

More information about the directed share issue and motive to deviate
from preferential rights

The directed share issue comprises a total of approx. SEK 17.6
million, of which approx. SEK 8 million is the initial directed new
share issue and approx. SEK 9.6 million relates to capital, which the
company can be supplied through the exercise of the attached
consideration-free warrants issued in connection with the directed
issue of shares. A total of 1,600,000 units, each consisting of one
(1) share and one (1) attached consideration-free warrant, are issued
at a price of SEK 5.00 per unit. This price has been based on
ExpreS2ion's volume-weighted average price (VWAP) during the 20
trading days ending two days before the decision on the directed new
issue, with a percentage discount of about 5 percent.

After the initial issue has been registered, the number of shares in
ExpreS2ion increases by 1,600,000, from 12,002,015 to 13,602,015. As
a result, the Company's share capital is increased by SEK
177,777.777778, from SEK 1,333,557.222223 to SEK 1,511,335.00. The
dilution for the Company's existing owners will be approximately 11.8
percent as a result of the initial issue.

In addition, as described above, an additional 1,600,000 attached
consideration-free warrants of series TO 3 are issued. Each warrant
entitles the holder to subscribe for one (1) new share at a price of
SEK 6.00 per share. The warrants have a conversion option once every
two months for a period of 12 months.

The existing owners that have subscribed for units in the directed
share issue are Peter Nilsson, John Andersson Moll, Kjell Nilsson,
Stefan Lundgren, Ejendommene Norgesvej 2 ApS and Konservesgaarden
A/S.

New investors that have subscribed for units are Oliver Molse, Modelio
Equity AB (publ), Gerhard Dal and Rolf R. Kuhnke.

The reason for the Board's proposal to deviate from some of the
shareholders' preferential rights is that the Board of Directors
considers it beneficial for the company and the shareholders to
strengthen the owner base partly by broadening the base of major
shareholders, and partly by enabling share ownership for new
strategic investors with special interest in the company, and to
avail of the opportunity to add new working capital to conditions
attractive to the company (especially the time and cost aspect of the
implementation of the capitalization). Through the directed share
issue, the company is supplied with working capital in order to work
towards set goals, in a cost and time-efficient manner and thereby
strengthen the company's financial position. The above aspects as
well as the prevailing market conditions have resulted in the
conclusion that, according to the Board's opinion, there have been
predominant reasons for deviating from the shareholders' preferential
rights to the benefit of the company and the shareholders in the long
term.

Certified Adviser

Sedermera Fondkommission

E-mail: CA@sedermera.se

Telephone: +46 40-615 14 10

For further information about ExpreS2ion Biotech Holding AB, please
contact:

Dr. Steen Klysner, CEO
Telephone: +45 2062 9908
E-mail: sk@expres2ionbio.com

This press release contains information that ExpreS2ion is obligated
to make public pursuant to the EU Market Abuse Regulation. The
information was submitted for publication through the agency of the
contact person set out above on February 28, 2019.

About ExpreS2ion

ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of
ExpreS2ion Biotech Holding AB with company register number
559033-3729. The subsidiary has developed a unique proprietary
platform technology, ExpreS2, that can be used for fast and efficient
preclinical and clinical development as well as robust production of
complex proteins for new vaccines and diagnostics. Since the Company
was founded in 2010, it has produced more than 300 proteins and 40
virus-like particles (VLPs) in collaboration with leading research
institutions and companies, demonstrating superior efficiency and
success rates. In addition, ExpreS2ion develops novel VLP based
vaccines through the joint venture AdaptVac ApS which was founded in
2017.

-----------------------------------------------------------
http://news.cision.com/se/expres2ion-biotechnologies/r/expres2ion-conduc...
https://mb.cision.com/Main/14402/2752494/999598.pdf

Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.